Thus, disruption of SFXN4 enhances the efficacy of platinum-based compounds and PARP inhibitors in a variety of ovarian cancer cell lines, including some with no known functional mutations in BRCA1/2 (A2780Cis, MDAH2774 (Table 1)). Here, SFXN4 is linked to ovarian carcinoma.